nodes	percent_of_prediction	percent_of_DWPC	metapath
Duloxetine—NPY1R—Endothelin Pathways—ADCY10—nephrolithiasis	0.0571	0.182	CbGpPWpGaD
Duloxetine—Blood potassium increased—Hydrochlorothiazide—nephrolithiasis	0.0254	0.0373	CcSEcCtD
Duloxetine—Gastric irritation—Hydrochlorothiazide—nephrolithiasis	0.0198	0.0291	CcSEcCtD
Duloxetine—Arrhythmia supraventricular—Hydrochlorothiazide—nephrolithiasis	0.0198	0.0291	CcSEcCtD
Duloxetine—Epigastric discomfort—Hydrochlorothiazide—nephrolithiasis	0.0146	0.0214	CcSEcCtD
Duloxetine—Creatine phosphokinase increased—Hydrochlorothiazide—nephrolithiasis	0.0146	0.0214	CcSEcCtD
Duloxetine—Sleep disturbance—Hydrochlorothiazide—nephrolithiasis	0.0137	0.0201	CcSEcCtD
Duloxetine—Sexual dysfunction—Hydrochlorothiazide—nephrolithiasis	0.0137	0.0201	CcSEcCtD
Duloxetine—Blood creatine phosphokinase increased—Hydrochlorothiazide—nephrolithiasis	0.0112	0.0164	CcSEcCtD
Duloxetine—Hyperlipidaemia—Hydrochlorothiazide—nephrolithiasis	0.0107	0.0156	CcSEcCtD
Duloxetine—Ventricular arrhythmia—Hydrochlorothiazide—nephrolithiasis	0.0104	0.0152	CcSEcCtD
Duloxetine—NPY1R—G alpha (i) signalling events—RGS14—nephrolithiasis	0.0101	0.0322	CbGpPWpGaD
Duloxetine—Feeling hot—Hydrochlorothiazide—nephrolithiasis	0.00978	0.0144	CcSEcCtD
Duloxetine—Gamma-glutamyltransferase increased—Hydrochlorothiazide—nephrolithiasis	0.00933	0.0137	CcSEcCtD
Duloxetine—HTR6—Monoamine GPCRs—CHRM3—nephrolithiasis	0.00875	0.0279	CbGpPWpGaD
Duloxetine—Rhabdomyolysis—Hydrochlorothiazide—nephrolithiasis	0.00868	0.0127	CcSEcCtD
Duloxetine—Musculoskeletal stiffness—Hydrochlorothiazide—nephrolithiasis	0.00856	0.0126	CcSEcCtD
Duloxetine—Nocturia—Hydrochlorothiazide—nephrolithiasis	0.00828	0.0121	CcSEcCtD
Duloxetine—Hypercholesterolaemia—Hydrochlorothiazide—nephrolithiasis	0.00812	0.0119	CcSEcCtD
Duloxetine—Coordination abnormal—Hydrochlorothiazide—nephrolithiasis	0.00782	0.0115	CcSEcCtD
Duloxetine—Musculoskeletal pain—Hydrochlorothiazide—nephrolithiasis	0.00777	0.0114	CcSEcCtD
Duloxetine—HTR6—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.00736	0.0234	CbGpPWpGaD
Duloxetine—Urine output increased—Hydrochlorothiazide—nephrolithiasis	0.00694	0.0102	CcSEcCtD
Duloxetine—Ecchymosis—Hydrochlorothiazide—nephrolithiasis	0.00694	0.0102	CcSEcCtD
Duloxetine—HTR2C—Monoamine GPCRs—CHRM3—nephrolithiasis	0.00645	0.0205	CbGpPWpGaD
Duloxetine—Sleep disorder—Hydrochlorothiazide—nephrolithiasis	0.00644	0.00945	CcSEcCtD
Duloxetine—Diabetes mellitus—Hydrochlorothiazide—nephrolithiasis	0.00641	0.0094	CcSEcCtD
Duloxetine—Polyuria—Hydrochlorothiazide—nephrolithiasis	0.00635	0.00931	CcSEcCtD
Duloxetine—Gastroenteritis—Hydrochlorothiazide—nephrolithiasis	0.00629	0.00923	CcSEcCtD
Duloxetine—Libido decreased—Hydrochlorothiazide—nephrolithiasis	0.00601	0.00882	CcSEcCtD
Duloxetine—Hot flush—Hydrochlorothiazide—nephrolithiasis	0.00596	0.00874	CcSEcCtD
Duloxetine—Increased appetite—Hydrochlorothiazide—nephrolithiasis	0.00593	0.0087	CcSEcCtD
Duloxetine—Menopausal symptoms—Hydrochlorothiazide—nephrolithiasis	0.00591	0.00867	CcSEcCtD
Duloxetine—Dermatitis exfoliative—Hydrochlorothiazide—nephrolithiasis	0.00591	0.00867	CcSEcCtD
Duloxetine—Atrial fibrillation—Hydrochlorothiazide—nephrolithiasis	0.00588	0.00863	CcSEcCtD
Duloxetine—Visual disturbance—Hydrochlorothiazide—nephrolithiasis	0.00588	0.00863	CcSEcCtD
Duloxetine—Thirst—Hydrochlorothiazide—nephrolithiasis	0.00586	0.00859	CcSEcCtD
Duloxetine—Renal impairment—Hydrochlorothiazide—nephrolithiasis	0.00586	0.00859	CcSEcCtD
Duloxetine—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A12—nephrolithiasis	0.00563	0.0179	CbGpPWpGaD
Duloxetine—HTR2A—Monoamine GPCRs—CHRM3—nephrolithiasis	0.0056	0.0178	CbGpPWpGaD
Duloxetine—Hyponatraemia—Hydrochlorothiazide—nephrolithiasis	0.0056	0.00821	CcSEcCtD
Duloxetine—Pain in extremity—Hydrochlorothiazide—nephrolithiasis	0.00557	0.00818	CcSEcCtD
Duloxetine—Gastrointestinal haemorrhage—Hydrochlorothiazide—nephrolithiasis	0.00557	0.00818	CcSEcCtD
Duloxetine—Disturbance in sexual arousal—Hydrochlorothiazide—nephrolithiasis	0.00553	0.00811	CcSEcCtD
Duloxetine—Affect lability—Hydrochlorothiazide—nephrolithiasis	0.00549	0.00805	CcSEcCtD
Duloxetine—Migraine—Hydrochlorothiazide—nephrolithiasis	0.00549	0.00805	CcSEcCtD
Duloxetine—HTR2C—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.00542	0.0172	CbGpPWpGaD
Duloxetine—Face oedema—Hydrochlorothiazide—nephrolithiasis	0.00538	0.00789	CcSEcCtD
Duloxetine—Mood swings—Hydrochlorothiazide—nephrolithiasis	0.00528	0.00775	CcSEcCtD
Duloxetine—Ataxia—Hydrochlorothiazide—nephrolithiasis	0.00524	0.00769	CcSEcCtD
Duloxetine—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A9—nephrolithiasis	0.00524	0.0167	CbGpPWpGaD
Duloxetine—Blood creatinine increased—Hydrochlorothiazide—nephrolithiasis	0.00522	0.00766	CcSEcCtD
Duloxetine—Liver function test abnormal—Hydrochlorothiazide—nephrolithiasis	0.00515	0.00755	CcSEcCtD
Duloxetine—Orthostatic hypotension—Hydrochlorothiazide—nephrolithiasis	0.00509	0.00747	CcSEcCtD
Duloxetine—Abdominal pain upper—Hydrochlorothiazide—nephrolithiasis	0.00509	0.00747	CcSEcCtD
Duloxetine—Breast disorder—Hydrochlorothiazide—nephrolithiasis	0.00504	0.00739	CcSEcCtD
Duloxetine—Cramp muscle—Hydrochlorothiazide—nephrolithiasis	0.00502	0.00736	CcSEcCtD
Duloxetine—Aspartate aminotransferase increased—Hydrochlorothiazide—nephrolithiasis	0.00502	0.00736	CcSEcCtD
Duloxetine—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A12—nephrolithiasis	0.00499	0.0159	CbGpPWpGaD
Duloxetine—Gastritis—Hydrochlorothiazide—nephrolithiasis	0.00493	0.00724	CcSEcCtD
Duloxetine—Muscular weakness—Hydrochlorothiazide—nephrolithiasis	0.00492	0.00721	CcSEcCtD
Duloxetine—Alanine aminotransferase increased—Hydrochlorothiazide—nephrolithiasis	0.00492	0.00721	CcSEcCtD
Duloxetine—Influenza—Hydrochlorothiazide—nephrolithiasis	0.00482	0.00707	CcSEcCtD
Duloxetine—Dysphagia—Hydrochlorothiazide—nephrolithiasis	0.00482	0.00707	CcSEcCtD
Duloxetine—Pancreatitis—Hydrochlorothiazide—nephrolithiasis	0.00472	0.00693	CcSEcCtD
Duloxetine—HTR2A—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.00471	0.015	CbGpPWpGaD
Duloxetine—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A9—nephrolithiasis	0.00464	0.0148	CbGpPWpGaD
Duloxetine—NPY1R—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.00458	0.0146	CbGpPWpGaD
Duloxetine—Dysuria—Hydrochlorothiazide—nephrolithiasis	0.00451	0.00661	CcSEcCtD
Duloxetine—Upper respiratory tract infection—Hydrochlorothiazide—nephrolithiasis	0.00448	0.00657	CcSEcCtD
Duloxetine—Pollakiuria—Hydrochlorothiazide—nephrolithiasis	0.00445	0.00653	CcSEcCtD
Duloxetine—Erectile dysfunction—Hydrochlorothiazide—nephrolithiasis	0.00444	0.00651	CcSEcCtD
Duloxetine—Photosensitivity reaction—Hydrochlorothiazide—nephrolithiasis	0.0044	0.00645	CcSEcCtD
Duloxetine—SLC6A4—NRF2 pathway—SLC2A9—nephrolithiasis	0.00439	0.014	CbGpPWpGaD
Duloxetine—Weight increased—Hydrochlorothiazide—nephrolithiasis	0.00439	0.00643	CcSEcCtD
Duloxetine—Hyperglycaemia—Hydrochlorothiazide—nephrolithiasis	0.00435	0.00637	CcSEcCtD
Duloxetine—Stevens-Johnson syndrome—Hydrochlorothiazide—nephrolithiasis	0.00426	0.00625	CcSEcCtD
Duloxetine—Acute coronary syndrome—Hydrochlorothiazide—nephrolithiasis	0.00424	0.00621	CcSEcCtD
Duloxetine—Renal failure—Hydrochlorothiazide—nephrolithiasis	0.00422	0.00619	CcSEcCtD
Duloxetine—Myocardial infarction—Hydrochlorothiazide—nephrolithiasis	0.00421	0.00618	CcSEcCtD
Duloxetine—Jaundice—Hydrochlorothiazide—nephrolithiasis	0.00419	0.00614	CcSEcCtD
Duloxetine—Urinary tract infection—Hydrochlorothiazide—nephrolithiasis	0.00418	0.00612	CcSEcCtD
Duloxetine—Conjunctivitis—Hydrochlorothiazide—nephrolithiasis	0.00418	0.00612	CcSEcCtD
Duloxetine—Epistaxis—Hydrochlorothiazide—nephrolithiasis	0.00405	0.00594	CcSEcCtD
Duloxetine—NPY1R—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.00392	0.0125	CbGpPWpGaD
Duloxetine—Hepatitis—Hydrochlorothiazide—nephrolithiasis	0.00386	0.00566	CcSEcCtD
Duloxetine—Hypoaesthesia—Hydrochlorothiazide—nephrolithiasis	0.00384	0.00563	CcSEcCtD
Duloxetine—Pharyngitis—Hydrochlorothiazide—nephrolithiasis	0.00383	0.00561	CcSEcCtD
Duloxetine—Oedema peripheral—Hydrochlorothiazide—nephrolithiasis	0.0038	0.00557	CcSEcCtD
Duloxetine—SLC6A2—NRF2 pathway—SLC2A9—nephrolithiasis	0.00378	0.012	CbGpPWpGaD
Duloxetine—Visual impairment—Hydrochlorothiazide—nephrolithiasis	0.00372	0.00545	CcSEcCtD
Duloxetine—SLC6A2—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.00369	0.0118	CbGpPWpGaD
Duloxetine—Erythema multiforme—Hydrochlorothiazide—nephrolithiasis	0.00365	0.00535	CcSEcCtD
Duloxetine—Tinnitus—Hydrochlorothiazide—nephrolithiasis	0.0036	0.00527	CcSEcCtD
Duloxetine—Flushing—Hydrochlorothiazide—nephrolithiasis	0.00358	0.00525	CcSEcCtD
Duloxetine—NPY1R—GPCR downstream signaling—RGS14—nephrolithiasis	0.00346	0.011	CbGpPWpGaD
Duloxetine—Arrhythmia—Hydrochlorothiazide—nephrolithiasis	0.00345	0.00505	CcSEcCtD
Duloxetine—Alopecia—Hydrochlorothiazide—nephrolithiasis	0.00341	0.005	CcSEcCtD
Duloxetine—SLC6A2—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.00338	0.0108	CbGpPWpGaD
Duloxetine—SLC6A2—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.00338	0.0108	CbGpPWpGaD
Duloxetine—Erythema—Hydrochlorothiazide—nephrolithiasis	0.00336	0.00492	CcSEcCtD
Duloxetine—SLC6A3—NRF2 pathway—SLC2A9—nephrolithiasis	0.00335	0.0106	CbGpPWpGaD
Duloxetine—Flatulence—Hydrochlorothiazide—nephrolithiasis	0.00331	0.00485	CcSEcCtD
Duloxetine—Tension—Hydrochlorothiazide—nephrolithiasis	0.00329	0.00483	CcSEcCtD
Duloxetine—Dysgeusia—Hydrochlorothiazide—nephrolithiasis	0.00329	0.00482	CcSEcCtD
Duloxetine—SLC6A3—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.00327	0.0104	CbGpPWpGaD
Duloxetine—Nervousness—Hydrochlorothiazide—nephrolithiasis	0.00326	0.00478	CcSEcCtD
Duloxetine—Back pain—Hydrochlorothiazide—nephrolithiasis	0.00325	0.00476	CcSEcCtD
Duloxetine—Muscle spasms—Hydrochlorothiazide—nephrolithiasis	0.00323	0.00473	CcSEcCtD
Duloxetine—Vision blurred—Hydrochlorothiazide—nephrolithiasis	0.00316	0.00464	CcSEcCtD
Duloxetine—Tremor—Hydrochlorothiazide—nephrolithiasis	0.00315	0.00461	CcSEcCtD
Duloxetine—NPY1R—Signaling by GPCR—RGS14—nephrolithiasis	0.00314	0.00999	CbGpPWpGaD
Duloxetine—Ill-defined disorder—Hydrochlorothiazide—nephrolithiasis	0.00312	0.00457	CcSEcCtD
Duloxetine—Anaemia—Hydrochlorothiazide—nephrolithiasis	0.0031	0.00455	CcSEcCtD
Duloxetine—Agitation—Hydrochlorothiazide—nephrolithiasis	0.00309	0.00453	CcSEcCtD
Duloxetine—Angioedema—Hydrochlorothiazide—nephrolithiasis	0.00307	0.0045	CcSEcCtD
Duloxetine—Malaise—Hydrochlorothiazide—nephrolithiasis	0.00303	0.00444	CcSEcCtD
Duloxetine—Vertigo—Hydrochlorothiazide—nephrolithiasis	0.00302	0.00442	CcSEcCtD
Duloxetine—Syncope—Hydrochlorothiazide—nephrolithiasis	0.00301	0.00442	CcSEcCtD
Duloxetine—Leukopenia—Hydrochlorothiazide—nephrolithiasis	0.00301	0.00441	CcSEcCtD
Duloxetine—SLC6A3—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.00299	0.00952	CbGpPWpGaD
Duloxetine—SLC6A3—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.00299	0.00952	CbGpPWpGaD
Duloxetine—NPY1R—GPCR ligand binding—CHRM3—nephrolithiasis	0.00299	0.00951	CbGpPWpGaD
Duloxetine—Palpitations—Hydrochlorothiazide—nephrolithiasis	0.00297	0.00435	CcSEcCtD
Duloxetine—Loss of consciousness—Hydrochlorothiazide—nephrolithiasis	0.00295	0.00433	CcSEcCtD
Duloxetine—Cough—Hydrochlorothiazide—nephrolithiasis	0.00293	0.0043	CcSEcCtD
Duloxetine—Myalgia—Hydrochlorothiazide—nephrolithiasis	0.00286	0.00419	CcSEcCtD
Duloxetine—Arthralgia—Hydrochlorothiazide—nephrolithiasis	0.00286	0.00419	CcSEcCtD
Duloxetine—Chest pain—Hydrochlorothiazide—nephrolithiasis	0.00286	0.00419	CcSEcCtD
Duloxetine—Anxiety—Hydrochlorothiazide—nephrolithiasis	0.00285	0.00418	CcSEcCtD
Duloxetine—Discomfort—Hydrochlorothiazide—nephrolithiasis	0.00282	0.00414	CcSEcCtD
Duloxetine—Dry mouth—Hydrochlorothiazide—nephrolithiasis	0.0028	0.0041	CcSEcCtD
Duloxetine—HTR6—G alpha (s) signalling events—PTH—nephrolithiasis	0.00278	0.00884	CbGpPWpGaD
Duloxetine—Confusional state—Hydrochlorothiazide—nephrolithiasis	0.00276	0.00405	CcSEcCtD
Duloxetine—Anaphylactic shock—Hydrochlorothiazide—nephrolithiasis	0.00274	0.00402	CcSEcCtD
Duloxetine—Oedema—Hydrochlorothiazide—nephrolithiasis	0.00274	0.00402	CcSEcCtD
Duloxetine—NPY1R—GPCR ligand binding—PTH—nephrolithiasis	0.00273	0.0087	CbGpPWpGaD
Duloxetine—Shock—Hydrochlorothiazide—nephrolithiasis	0.0027	0.00395	CcSEcCtD
Duloxetine—Thrombocytopenia—Hydrochlorothiazide—nephrolithiasis	0.00268	0.00393	CcSEcCtD
Duloxetine—Tachycardia—Hydrochlorothiazide—nephrolithiasis	0.00267	0.00392	CcSEcCtD
Duloxetine—Hyperhidrosis—Hydrochlorothiazide—nephrolithiasis	0.00265	0.00388	CcSEcCtD
Duloxetine—Anorexia—Hydrochlorothiazide—nephrolithiasis	0.00261	0.00383	CcSEcCtD
Duloxetine—SLC6A2—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.00256	0.00815	CbGpPWpGaD
Duloxetine—SLC6A2—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.00256	0.00815	CbGpPWpGaD
Duloxetine—Musculoskeletal discomfort—Hydrochlorothiazide—nephrolithiasis	0.0025	0.00366	CcSEcCtD
Duloxetine—HTR2A—GPCRs, Other—CHRM3—nephrolithiasis	0.00249	0.00791	CbGpPWpGaD
Duloxetine—Insomnia—Hydrochlorothiazide—nephrolithiasis	0.00248	0.00363	CcSEcCtD
Duloxetine—Paraesthesia—Hydrochlorothiazide—nephrolithiasis	0.00246	0.00361	CcSEcCtD
Duloxetine—Somnolence—Hydrochlorothiazide—nephrolithiasis	0.00244	0.00357	CcSEcCtD
Duloxetine—Dyspepsia—Hydrochlorothiazide—nephrolithiasis	0.00241	0.00354	CcSEcCtD
Duloxetine—Decreased appetite—Hydrochlorothiazide—nephrolithiasis	0.00238	0.00349	CcSEcCtD
Duloxetine—SLC6A2—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.00238	0.00757	CbGpPWpGaD
Duloxetine—SLC6A2—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.00238	0.00757	CbGpPWpGaD
Duloxetine—Fatigue—Hydrochlorothiazide—nephrolithiasis	0.00236	0.00346	CcSEcCtD
Duloxetine—Constipation—Hydrochlorothiazide—nephrolithiasis	0.00234	0.00344	CcSEcCtD
Duloxetine—Pain—Hydrochlorothiazide—nephrolithiasis	0.00234	0.00344	CcSEcCtD
Duloxetine—NPY1R—GPCR downstream signaling—DGKH—nephrolithiasis	0.00234	0.00743	CbGpPWpGaD
Duloxetine—SLC6A3—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.00227	0.00722	CbGpPWpGaD
Duloxetine—SLC6A3—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.00227	0.00722	CbGpPWpGaD
Duloxetine—Feeling abnormal—Hydrochlorothiazide—nephrolithiasis	0.00226	0.00331	CcSEcCtD
Duloxetine—Gastrointestinal pain—Hydrochlorothiazide—nephrolithiasis	0.00224	0.00329	CcSEcCtD
Duloxetine—HTR2C—G alpha (q) signalling events—DGKH—nephrolithiasis	0.00223	0.00708	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—ADCY10—nephrolithiasis	0.00218	0.00694	CbGpPWpGaD
Duloxetine—Urticaria—Hydrochlorothiazide—nephrolithiasis	0.00218	0.00319	CcSEcCtD
Duloxetine—Abdominal pain—Hydrochlorothiazide—nephrolithiasis	0.00217	0.00318	CcSEcCtD
Duloxetine—Body temperature increased—Hydrochlorothiazide—nephrolithiasis	0.00217	0.00318	CcSEcCtD
Duloxetine—SLC6A2—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.00212	0.00675	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—DGKH—nephrolithiasis	0.00212	0.00675	CbGpPWpGaD
Duloxetine—SLC6A3—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.00211	0.00671	CbGpPWpGaD
Duloxetine—SLC6A3—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.00211	0.00671	CbGpPWpGaD
Duloxetine—SLC6A2—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.00211	0.0067	CbGpPWpGaD
Duloxetine—SLC6A2—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.00211	0.0067	CbGpPWpGaD
Duloxetine—Hypersensitivity—Hydrochlorothiazide—nephrolithiasis	0.00202	0.00296	CcSEcCtD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—DGKH—nephrolithiasis	0.00199	0.00634	CbGpPWpGaD
Duloxetine—CYP1A2—Phase II conjugation—SLC26A1—nephrolithiasis	0.00199	0.00633	CbGpPWpGaD
Duloxetine—Asthenia—Hydrochlorothiazide—nephrolithiasis	0.00197	0.00288	CcSEcCtD
Duloxetine—Pruritus—Hydrochlorothiazide—nephrolithiasis	0.00194	0.00284	CcSEcCtD
Duloxetine—HTR2A—G alpha (q) signalling events—DGKH—nephrolithiasis	0.00193	0.00615	CbGpPWpGaD
Duloxetine—SLC6A3—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.00188	0.00598	CbGpPWpGaD
Duloxetine—SLC6A2—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.00188	0.00597	CbGpPWpGaD
Duloxetine—Diarrhoea—Hydrochlorothiazide—nephrolithiasis	0.00187	0.00275	CcSEcCtD
Duloxetine—SLC6A3—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.00187	0.00594	CbGpPWpGaD
Duloxetine—SLC6A3—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.00187	0.00594	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—RGS14—nephrolithiasis	0.00185	0.0059	CbGpPWpGaD
Duloxetine—Dizziness—Hydrochlorothiazide—nephrolithiasis	0.00181	0.00266	CcSEcCtD
Duloxetine—Vomiting—Hydrochlorothiazide—nephrolithiasis	0.00174	0.00256	CcSEcCtD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—DGKH—nephrolithiasis	0.00173	0.0055	CbGpPWpGaD
Duloxetine—Rash—Hydrochlorothiazide—nephrolithiasis	0.00173	0.00253	CcSEcCtD
Duloxetine—Dermatitis—Hydrochlorothiazide—nephrolithiasis	0.00173	0.00253	CcSEcCtD
Duloxetine—SLC6A2—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.00172	0.00546	CbGpPWpGaD
Duloxetine—SLC6A2—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.00172	0.00546	CbGpPWpGaD
Duloxetine—Headache—Hydrochlorothiazide—nephrolithiasis	0.00172	0.00252	CcSEcCtD
Duloxetine—HTR6—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.00169	0.00538	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—CHRM3—nephrolithiasis	0.00169	0.00537	CbGpPWpGaD
Duloxetine—SLC6A3—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.00166	0.00529	CbGpPWpGaD
Duloxetine—Nausea—Hydrochlorothiazide—nephrolithiasis	0.00163	0.00239	CcSEcCtD
Duloxetine—HTR2C—G alpha (q) signalling events—CHRM3—nephrolithiasis	0.00161	0.00512	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—PTH—nephrolithiasis	0.00154	0.00491	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—CHRM3—nephrolithiasis	0.00153	0.00488	CbGpPWpGaD
Duloxetine—SLC6A3—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.00152	0.00484	CbGpPWpGaD
Duloxetine—SLC6A3—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.00152	0.00484	CbGpPWpGaD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.00145	0.00461	CbGpPWpGaD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—CHRM3—nephrolithiasis	0.00144	0.00458	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—PTH—nephrolithiasis	0.0014	0.00446	CbGpPWpGaD
Duloxetine—HTR2A—G alpha (q) signalling events—CHRM3—nephrolithiasis	0.0014	0.00445	CbGpPWpGaD
Duloxetine—CYP2D6—Biological oxidations—SLC26A1—nephrolithiasis	0.00137	0.00437	CbGpPWpGaD
Duloxetine—SLC6A2—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.0013	0.00414	CbGpPWpGaD
Duloxetine—SLC6A2—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.0013	0.00414	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—RGS14—nephrolithiasis	0.00128	0.00406	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.00125	0.00399	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—DGKH—nephrolithiasis	0.00125	0.00399	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—CHRM3—nephrolithiasis	0.00125	0.00398	CbGpPWpGaD
Duloxetine—HTR2C—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.00124	0.00396	CbGpPWpGaD
Duloxetine—SLC6A2—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.00121	0.00385	CbGpPWpGaD
Duloxetine—SLC6A2—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.00121	0.00385	CbGpPWpGaD
Duloxetine—CYP1A2—Biological oxidations—SLC26A1—nephrolithiasis	0.00116	0.00371	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—RGS14—nephrolithiasis	0.00116	0.00369	CbGpPWpGaD
Duloxetine—SLC6A3—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.00115	0.00367	CbGpPWpGaD
Duloxetine—SLC6A3—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.00115	0.00367	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—CHRM3—nephrolithiasis	0.0011	0.00351	CbGpPWpGaD
Duloxetine—HTR2A—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.00108	0.00344	CbGpPWpGaD
Duloxetine—SLC6A2—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.00108	0.00343	CbGpPWpGaD
Duloxetine—SLC6A2—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.00108	0.00343	CbGpPWpGaD
Duloxetine—SLC6A3—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.00107	0.00341	CbGpPWpGaD
Duloxetine—SLC6A3—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.00107	0.00341	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.00107	0.00339	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—PTH—nephrolithiasis	0.00101	0.00321	CbGpPWpGaD
Duloxetine—SLC6A3—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.000955	0.00304	CbGpPWpGaD
Duloxetine—SLC6A3—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.000955	0.00304	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—RGS14—nephrolithiasis	0.000939	0.00299	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.000926	0.00295	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—CHRM3—nephrolithiasis	0.000906	0.00288	CbGpPWpGaD
Duloxetine—SLC6A2—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.000862	0.00274	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—DGKH—nephrolithiasis	0.000861	0.00274	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—RGS14—nephrolithiasis	0.000853	0.00271	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—PTH—nephrolithiasis	0.000828	0.00264	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—RGS14—nephrolithiasis	0.000816	0.0026	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—CHRM3—nephrolithiasis	0.000812	0.00258	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—ADCY10—nephrolithiasis	0.000805	0.00256	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—DGKH—nephrolithiasis	0.000782	0.00249	CbGpPWpGaD
Duloxetine—SLC6A3—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.000764	0.00243	CbGpPWpGaD
Duloxetine—CYP1A2—urine—nephrolithiasis	0.000746	0.189	CbGeAlD
Duloxetine—HTR2C—GPCR ligand binding—PTH—nephrolithiasis	0.000742	0.00236	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—RGS14—nephrolithiasis	0.000741	0.00236	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—CHRM3—nephrolithiasis	0.000705	0.00224	CbGpPWpGaD
Duloxetine—NPY1R—renal system—nephrolithiasis	0.000699	0.178	CbGeAlD
Duloxetine—HTR6—Signaling Pathways—RGS14—nephrolithiasis	0.000684	0.00218	CbGpPWpGaD
Duloxetine—NPY1R—cortex of kidney—nephrolithiasis	0.000658	0.167	CbGeAlD
Duloxetine—HTR2A—GPCR ligand binding—PTH—nephrolithiasis	0.000645	0.00205	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—DGKH—nephrolithiasis	0.000634	0.00202	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—CHRM3—nephrolithiasis	0.000623	0.00198	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—ADCY10—nephrolithiasis	0.000593	0.00189	CbGpPWpGaD
Duloxetine—HTR2A—urine—nephrolithiasis	0.000583	0.148	CbGeAlD
Duloxetine—HTR2C—Signaling by GPCR—DGKH—nephrolithiasis	0.000576	0.00183	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—PTH—nephrolithiasis	0.00057	0.00181	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—CHRM3—nephrolithiasis	0.000566	0.0018	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—DGKH—nephrolithiasis	0.000551	0.00175	CbGpPWpGaD
Duloxetine—CYP2D6—urine—nephrolithiasis	0.000531	0.135	CbGeAlD
Duloxetine—HTR6—Signaling by GPCR—PTH—nephrolithiasis	0.000517	0.00165	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—ADCY10—nephrolithiasis	0.000515	0.00164	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—RGS14—nephrolithiasis	0.000504	0.0016	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—DGKH—nephrolithiasis	0.0005	0.00159	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000462	0.00147	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—DGKH—nephrolithiasis	0.000462	0.00147	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—CHRM3—nephrolithiasis	0.000459	0.00146	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—RGS14—nephrolithiasis	0.000438	0.00139	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—PTH—nephrolithiasis	0.00042	0.00133	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—CHRM3—nephrolithiasis	0.000417	0.00133	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—SPP1—nephrolithiasis	0.000416	0.00132	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—CHRM3—nephrolithiasis	0.000398	0.00127	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—PTH—nephrolithiasis	0.000381	0.00121	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—PTH—nephrolithiasis	0.000364	0.00116	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—CHRM3—nephrolithiasis	0.000362	0.00115	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—DGKH—nephrolithiasis	0.00034	0.00108	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.00034	0.00108	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CHRM3—nephrolithiasis	0.000334	0.00106	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—PTH—nephrolithiasis	0.000331	0.00105	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GRHPR—nephrolithiasis	0.00031	0.000987	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PTH—nephrolithiasis	0.000306	0.000972	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—DGKH—nephrolithiasis	0.000296	0.00094	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000296	0.00094	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—AGXT—nephrolithiasis	0.000276	0.00088	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GRHPR—nephrolithiasis	0.000263	0.000836	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CHRM3—nephrolithiasis	0.000246	0.000783	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—APRT—nephrolithiasis	0.000235	0.000748	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—SLC26A1—nephrolithiasis	0.000235	0.000748	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—AGXT—nephrolithiasis	0.000234	0.000745	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PTH—nephrolithiasis	0.000225	0.000716	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CHRM3—nephrolithiasis	0.000214	0.00068	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—SLC26A1—nephrolithiasis	0.000199	0.000634	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—APRT—nephrolithiasis	0.000199	0.000634	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PTH—nephrolithiasis	0.000195	0.000622	CbGpPWpGaD
Duloxetine—CYP1A2—renal system—nephrolithiasis	0.000182	0.0463	CbGeAlD
Duloxetine—CYP2D6—Metabolism—AQP1—nephrolithiasis	0.000168	0.000533	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—SPP1—nephrolithiasis	0.000153	0.000488	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CHRM3—nephrolithiasis	0.000151	0.000482	CbGpPWpGaD
Duloxetine—HTR2A—renal system—nephrolithiasis	0.000143	0.0362	CbGeAlD
Duloxetine—CYP1A2—Metabolism—AQP1—nephrolithiasis	0.000142	0.000452	CbGpPWpGaD
Duloxetine—HTR2A—kidney—nephrolithiasis	0.000138	0.035	CbGeAlD
Duloxetine—CYP2D6—renal system—nephrolithiasis	0.00013	0.033	CbGeAlD
Duloxetine—CYP1A2—Metabolism—CHRM3—nephrolithiasis	0.000128	0.000408	CbGpPWpGaD
Duloxetine—CYP2D6—kidney—nephrolithiasis	0.000126	0.0319	CbGeAlD
Duloxetine—HTR2C—Signaling Pathways—SPP1—nephrolithiasis	0.000113	0.00036	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—SPP1—nephrolithiasis	9.81e-05	0.000312	CbGpPWpGaD
